CME provided by Research to Practice. This symposium is supported by Eisai Inc,Merck, Seattle Genetics, and TESARO, a GSK Company.
Neil Love, MD, Research to Practice, Miami, FL
Krishnansu S. Tewari, MD, University of California, Irvine, Irvine, CA
Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA
Michael J. Birrer, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
David M O’Malley, MD, The Ohio State University, Columbus, OH
This CME symposium will focus on th current and future role of immune checkpoint inhibitors and other novel therapies in the management of patients with ovarian, cervical, and endometrial cancer. Research To Practice (RTP) president and medical oncologist Dr Neil Love will moderate the program, and four clinical investigators will serve as the faculty. Leading up to SGO, each faculty member will be provide RTP with a number of interesting cases from their practices of patients with each disease for whom treatment with an approved or investigational agent was considered and/or administered. The activity will be divided into 4 modules, each featuring a blend of moderated case and panel discussion and a faculty member-led review of related scientific data and ongoing research. To make the program more interactive and relevant to those in the room, clinician attendees will use networked iPads to complete a premeeting survey centered on the cases and topics to be presented. Survey results will be interspersed throughout the discussions within each module to foster additional debate among the panelists and ensure a variety of perspectives emerge. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge.